Selected research
Industry Research
Lipid Nanoparticle Solutions Industry Research Report 2026
Market perspective
The global Lipid Nanoparticle Solutions market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lipid Nanoparticle Solutions market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lipid Nanoparticle Solutions market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lipid Nanoparticle Solutions market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lipid Nanoparticle Solutions include Merck, Cytiva, GenScript, Creative Biolabs, WuXi STA, Carcell, Croda International, Detai Biotechnology and Waters, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lipid Nanoparticle Solutions market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lipid Nanoparticle Solutions.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lipid Nanoparticle Solutions Market by Company
Merck
Cytiva
GenScript
Creative Biolabs
WuXi STA
Carcell
Croda International
Detai Biotechnology
Waters
MicroNano Biologics
Precigenome
Evonik
Avanti Polar Lipids
Genevant Sciences
Exelead
Nippon Fine Chemical
Lipoid
Lipid Nanoparticle Solutions Segment by Type
Solid Lipid Nanoparticles
Nanostructured Lipid Carriers
Cationic Lipid-Nucleic Acid Complexes
Lipid Nanoparticle Solutions Segment by Application
Gene Therapy
Vaccine Development
Cancer Treatment
Lipid Nanoparticle Solutions Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid Nanoparticle Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lipid Nanoparticle Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid Nanoparticle Solutions.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lipid Nanoparticle Solutions companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Solid Lipid Nanoparticles
- Nanostructured Lipid Carriers
- Cationic Lipid-Nucleic Acid Complexes
Applications
- Gene Therapy
- Vaccine Development
- Cancer Treatment
Companies covered
- Merck
- Cytiva
- GenScript
- Creative Biolabs
- WuXi STA
- Carcell
- Croda International
- Detai Biotechnology
- Waters
- MicroNano Biologics
- Precigenome
- Evonik
- Avanti Polar Lipids
- Genevant Sciences
- Exelead
- Nippon Fine Chemical
- Lipoid
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lipid Nanoparticle Solutions by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Solid Lipid Nanoparticles
- 2.2.3 Nanostructured Lipid Carriers
- 2.2.4 Cationic Lipid-Nucleic Acid Complexes
- 2.3 Lipid Nanoparticle Solutions by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Gene Therapy
- 2.3.3 Vaccine Development
- 2.3.4 Cancer Treatment
- 2.4 Assumptions and Limitations
3 Lipid Nanoparticle Solutions Breakdown Data by Type
- 3.1 Global Lipid Nanoparticle Solutions Historic Market Size by Type (2021-2026)
- 3.2 Global Lipid Nanoparticle Solutions Forecasted Market Size by Type (2027-2032)
4 Lipid Nanoparticle Solutions Breakdown Data by Application
- 4.1 Global Lipid Nanoparticle Solutions Historic Market Size by Application (2021-2026)
- 4.2 Global Lipid Nanoparticle Solutions Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lipid Nanoparticle Solutions Market Perspective (2021-2032)
- 5.2 Global Lipid Nanoparticle Solutions Growth Trends by Region
- 5.2.1 Global Lipid Nanoparticle Solutions Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lipid Nanoparticle Solutions Historic Market Size by Region (2021-2026)
- 5.2.3 Lipid Nanoparticle Solutions Forecasted Market Size by Region (2027-2032)
- 5.3 Lipid Nanoparticle Solutions Market Dynamics
- 5.3.1 Lipid Nanoparticle Solutions Industry Trends
- 5.3.2 Lipid Nanoparticle Solutions Market Drivers
- 5.3.3 Lipid Nanoparticle Solutions Market Challenges
- 5.3.4 Lipid Nanoparticle Solutions Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lipid Nanoparticle Solutions Players by Revenue
- 6.1.1 Global Top Lipid Nanoparticle Solutions Players by Revenue (2021-2026)
- 6.1.2 Global Lipid Nanoparticle Solutions Revenue Market Share by Players (2021-2026)
- 6.2 Global Lipid Nanoparticle Solutions Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lipid Nanoparticle Solutions Head Office and Area Served
- 6.4 Global Lipid Nanoparticle Solutions Players, Product Type & Application
- 6.5 Global Lipid Nanoparticle Solutions Manufacturers Established Date
- 6.6 Global Lipid Nanoparticle Solutions Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lipid Nanoparticle Solutions Market Size (2021-2032)
- 7.2 North America Lipid Nanoparticle Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lipid Nanoparticle Solutions Market Size by Country (2021-2026)
- 7.4 North America Lipid Nanoparticle Solutions Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lipid Nanoparticle Solutions Market Size (2021-2032)
- 8.2 Europe Lipid Nanoparticle Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lipid Nanoparticle Solutions Market Size by Country (2021-2026)
- 8.4 Europe Lipid Nanoparticle Solutions Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lipid Nanoparticle Solutions Market Size (2021-2032)
- 9.2 Asia-Pacific Lipid Nanoparticle Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lipid Nanoparticle Solutions Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lipid Nanoparticle Solutions Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lipid Nanoparticle Solutions Market Size (2021-2032)
- 10.2 South America Lipid Nanoparticle Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lipid Nanoparticle Solutions Market Size by Country (2021-2026)
- 10.4 South America Lipid Nanoparticle Solutions Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lipid Nanoparticle Solutions Market Size (2021-2032)
- 11.2 Middle East & Africa Lipid Nanoparticle Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lipid Nanoparticle Solutions Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lipid Nanoparticle Solutions Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.1.4 Merck Lipid Nanoparticle Solutions Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Cytiva
- 12.2.1 Cytiva Company Information
- 12.2.2 Cytiva Business Overview
- 12.2.3 Cytiva Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.2.4 Cytiva Lipid Nanoparticle Solutions Product Portfolio
- 12.2.5 Cytiva Recent Developments
- 12.3 GenScript
- 12.3.1 GenScript Company Information
- 12.3.2 GenScript Business Overview
- 12.3.3 GenScript Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.3.4 GenScript Lipid Nanoparticle Solutions Product Portfolio
- 12.3.5 GenScript Recent Developments
- 12.4 Creative Biolabs
- 12.4.1 Creative Biolabs Company Information
- 12.4.2 Creative Biolabs Business Overview
- 12.4.3 Creative Biolabs Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.4.4 Creative Biolabs Lipid Nanoparticle Solutions Product Portfolio
- 12.4.5 Creative Biolabs Recent Developments
- 12.5 WuXi STA
- 12.5.1 WuXi STA Company Information
- 12.5.2 WuXi STA Business Overview
- 12.5.3 WuXi STA Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.5.4 WuXi STA Lipid Nanoparticle Solutions Product Portfolio
- 12.5.5 WuXi STA Recent Developments
- 12.6 Carcell
- 12.6.1 Carcell Company Information
- 12.6.2 Carcell Business Overview
- 12.6.3 Carcell Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.6.4 Carcell Lipid Nanoparticle Solutions Product Portfolio
- 12.6.5 Carcell Recent Developments
- 12.7 Croda International
- 12.7.1 Croda International Company Information
- 12.7.2 Croda International Business Overview
- 12.7.3 Croda International Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.7.4 Croda International Lipid Nanoparticle Solutions Product Portfolio
- 12.7.5 Croda International Recent Developments
- 12.8 Detai Biotechnology
- 12.8.1 Detai Biotechnology Company Information
- 12.8.2 Detai Biotechnology Business Overview
- 12.8.3 Detai Biotechnology Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.8.4 Detai Biotechnology Lipid Nanoparticle Solutions Product Portfolio
- 12.8.5 Detai Biotechnology Recent Developments
- 12.9 Waters
- 12.9.1 Waters Company Information
- 12.9.2 Waters Business Overview
- 12.9.3 Waters Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.9.4 Waters Lipid Nanoparticle Solutions Product Portfolio
- 12.9.5 Waters Recent Developments
- 12.10 MicroNano Biologics
- 12.10.1 MicroNano Biologics Company Information
- 12.10.2 MicroNano Biologics Business Overview
- 12.10.3 MicroNano Biologics Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.10.4 MicroNano Biologics Lipid Nanoparticle Solutions Product Portfolio
- 12.10.5 MicroNano Biologics Recent Developments
- 12.11 Precigenome
- 12.11.1 Precigenome Company Information
- 12.11.2 Precigenome Business Overview
- 12.11.3 Precigenome Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.11.4 Precigenome Lipid Nanoparticle Solutions Product Portfolio
- 12.11.5 Precigenome Recent Developments
- 12.12 Evonik
- 12.12.1 Evonik Company Information
- 12.12.2 Evonik Business Overview
- 12.12.3 Evonik Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.12.4 Evonik Lipid Nanoparticle Solutions Product Portfolio
- 12.12.5 Evonik Recent Developments
- 12.13 Avanti Polar Lipids
- 12.13.1 Avanti Polar Lipids Company Information
- 12.13.2 Avanti Polar Lipids Business Overview
- 12.13.3 Avanti Polar Lipids Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.13.4 Avanti Polar Lipids Lipid Nanoparticle Solutions Product Portfolio
- 12.13.5 Avanti Polar Lipids Recent Developments
- 12.14 Genevant Sciences
- 12.14.1 Genevant Sciences Company Information
- 12.14.2 Genevant Sciences Business Overview
- 12.14.3 Genevant Sciences Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.14.4 Genevant Sciences Lipid Nanoparticle Solutions Product Portfolio
- 12.14.5 Genevant Sciences Recent Developments
- 12.15 Exelead
- 12.15.1 Exelead Company Information
- 12.15.2 Exelead Business Overview
- 12.15.3 Exelead Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.15.4 Exelead Lipid Nanoparticle Solutions Product Portfolio
- 12.15.5 Exelead Recent Developments
- 12.16 Nippon Fine Chemical
- 12.16.1 Nippon Fine Chemical Company Information
- 12.16.2 Nippon Fine Chemical Business Overview
- 12.16.3 Nippon Fine Chemical Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.16.4 Nippon Fine Chemical Lipid Nanoparticle Solutions Product Portfolio
- 12.16.5 Nippon Fine Chemical Recent Developments
- 12.17 Lipoid
- 12.17.1 Lipoid Company Information
- 12.17.2 Lipoid Business Overview
- 12.17.3 Lipoid Revenue in Lipid Nanoparticle Solutions Business (2021-2026)
- 12.17.4 Lipoid Lipid Nanoparticle Solutions Product Portfolio
- 12.17.5 Lipoid Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst